Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?

Vogelstein, 2004, Cancer genes and the pathways they control, Nat Med, 10, 789, 10.1038/nm1087 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med, 2, 561, 10.1038/nm0596-561 Bartram, 1985, bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia, J Exp Med, 162, 2175, 10.1084/jem.162.6.2175 Lawrence, 2014, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, 505, 495, 10.1038/nature12912 Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095 Frampton, 2013, Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, 31, 1023, 10.1038/nbt.2696 Von Hoff, 2010, Pilot study using molecular profiling of patients′ tumors to find potential targets and select treatments for their refractory cancers, J Clin Oncol, 28, 4877, 10.1200/JCO.2009.26.5983 Tsimberidou, 2014, Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses, Clin Cancer Res, 20, 4827, 10.1158/1078-0432.CCR-14-0603 Ross, 2015, Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies, JAMA Oncol, 1, 40, 10.1001/jamaoncol.2014.216 Le Tourneau, 2015, Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Lancet Oncol, 16, 1324, 10.1016/S1470-2045(15)00188-6 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Wheler, 2015, Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy, J Clin Oncol, 33, S11019, 10.1200/jco.2015.33.15_suppl.11019 Friedman, 2015, Precision medicine for cancer with next-generation functional diagnostics, Nat Rev Cancer, 15, 747, 10.1038/nrc4015 Hartwell, 1997, Integrating genetic approaches into the discovery of anticancer drugs, Science, 278, 1064, 10.1126/science.278.5340.1064 Margulies, 2005, Genome sequencing in microfabricated high-density picolitre reactors, Nature, 437, 376, 10.1038/nature03959 Shendure, 2005, Accurate multiplex polony sequencing of an evolved bacterial genome, Science, 309, 1728, 10.1126/science.1117389 Xuan, 2013, Next-generation sequencing in the clinic: promises and challenges, Cancer Lett, 340, 284, 10.1016/j.canlet.2012.11.025 Dienstmann, 2015, Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors, Cancer Discov, 5, 118, 10.1158/2159-8290.CD-14-1118 Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205 Fojo, 2014, Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture, JAMA Otolaryngol Head Neck Surg, 140, 1225, 10.1001/jamaoto.2014.1570 McGranahan, 2015, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer Cell, 27, 15, 10.1016/j.ccell.2014.12.001 Campesato, 2015, Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice, Oncotarget, 6, 34221, 10.18632/oncotarget.5950 Redig, 2015, Basket trials and the evolution of clinical trial design in an era of genomic medicine, J Clin Oncol, 33, 975, 10.1200/JCO.2014.59.8433 Mullard, 2015, NCI-MATCH trial pushes cancer umbrella trial paradigm, Nat Rev Drug Discov, 14, 513, 10.1038/nrd4694 Burris, 2015, MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.tps11111